Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.52 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.47 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812303 | 0.92 | L3MBTL1 (0.55) | L3MBTL1L3MBTL3KDM4EMEN1ALDH1A1 | |
| SCHEMBL12625723 | 0.86 | HRH3 (0.63) | L3MBTL1L3MBTL3HRH3MBTD1TP53BP1 | |
| SCHEMBL1812592 | 0.86 | L3MBTL3 (0.52) | L3MBTL1L3MBTL3HRH3MBTD1TP53BP1 | |
| SCHEMBL1735171 | 0.79 | L3MBTL1 (0.81) | L3MBTL1L3MBTL3KDM4EMEN1ALDH1A1 | |
| SCHEMBL13024627 | 0.79 | L3MBTL1 (0.81) | L3MBTL1L3MBTL3KDM4EMEN1ALDH1A1 | |
| SCHEMBL1813537 | 0.78 | MGLL (0.57) | L3MBTL1L3MBTL3KDM4EMEN1ALDH1A1 | |
| SCHEMBL1809657 | 0.78 | MGLL (0.64) | L3MBTL1L3MBTL3KDM4EMEN1ALDH1A1 | |
| SCHEMBL1814395 | 0.77 | L3MBTL1 (0.56) | L3MBTL1L3MBTL3KDM4EMEN1ALDH1A1 | |
| SCHEMBL1812407 | 0.77 | MGLL (0.57) | L3MBTL1L3MBTL3KDM4EMEN1ALDH1A1 | |
| SCHEMBL19126435 | 0.76 | L3MBTL1 (0.45) | L3MBTL1L3MBTL3KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | claimed |
| EP-2074088-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth (US) | 2009-07-01 | — | — | EP | claimed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | claimed |
| WO-2008045371-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-04-17 | — | — | WO | claimed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935719-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119458-A1 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | HNMT, HRH4, HRH3 | L3MBTL1 4246/4885L3MBTL3 2875/4885KDM4E 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.